Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amryt Pharma Plc ADR (NQ: AMYT )

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Apr 11, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Amryt Pharma Plc ADR

< Previous 1 2 3 Next >
Top 5 Health Care Stocks That Are Ticking Portfolio Bombs
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 18, 2023
Via Benzinga
Why Shares of Amryt Pharma Jumped This Week
A takeover bid by an Italian pharmaceutical and healthcare company boosted Amryt's shares. 
Via The Motley Fool
Recap: Amryt Pharma Q3 Earnings
Amryt Pharma (NASDAQ:AMYT) reported its Q3 earnings results on Thursday, November 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Filsuvez's European Approval Adds Growth Driver For Amryt Pharma
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 10, 2023
Via Benzinga
Recap: Amryt Pharma Q1 Earnings
Amryt Pharma (NASDAQ:AMYT) reported its Q1 earnings results on Wednesday, May 4, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Amryt Shares Trading Higher As EMA Endorses Approval Of Filsuvez In Genetic Skin Disease
Via Benzinga
S&P 500 Gains 0.6%; Albireo Pharma Shares Spike Higher
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining more than 200 points on Monday. 
Via Benzinga
Why Cutera Shares Are Trading Lower By 23%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers CinCor Pharma, Inc. (NASDAQ: CINC) shares jumped 137% to $27.93 after AstraZeneca announced it will acquire the company for $26 per share in cash. 
Via Benzinga
Amryt Posts Long-Term Safety, Efficacy Mycapssa Data In Acromegaly Patients
Amryt Pharma Plc (NASDAQ: AMYT) has  
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Nasdaq Surges Over 200 Points; Crude Oil Rises 2%
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 200 points on Monday. 
Via Benzinga
Tesla, Zillow, Albireo Pharma And Some Other Big Stocks Moving Higher On Monday
U.S. stocks traded higher, with the Dow Jones gaining more than 150 points on Monday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
US Stocks Open Higher; Dow Rises 150 Points
U.S. stocks traded higher this morning, with the Dow Jones gaining around 150 points on Monday. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 9, 2023
Via Benzinga
Adobe To Rally 25%? Here Are 10 Other Analyst Forecasts For Monday
Via Benzinga
Italian Privately Held Chiesi Farmaceutici To Acquire Amryt Pharma For $1.25B
Italian family-controlled global pharmaceutical company Chiesi Farmaceutici S.p.A. has agreed to acquire Amryt Pharma Plc (NASDAQ: AMYT) for an implied value of $1.25 billion in upfront consideration. 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Why CinCor Pharma Shares Are Trading Higher By 140%; Here Are 20 Stocks Moving Premarket
Gainers CinCor Pharma, Inc. (NASDAQ: CINC) rose 140.2% to $28.30 in pre-market trading after AstraZeneca announced plans to buy the company for up to $1.8 billion. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
We're starting off the week with a look at the biggest pre-market stock movers traders need to know about on Monday morning! 
Via InvestorPlace
Important Biotech Catalysts For September 8, 2022 - End Of The Day Summary
Via Benzinga
Amryt Secures UK Regulatory Nod And Orphan Disease Status For Skin Disorder Candidate
The Medical Healthcare & Products Regulatory Agency (MHRA) has granted Marketing Authorisation Approval (MAA) and Orphan Disease Designation (ODD) for Amryt’s (NASDAQ: AMYT) lead candidate Filsuvez for... 
Via Benzinga
The Daily Biotech Pulse: Much Awaited FDA Nod For Novavax's COVID-19 Shot, DSMB Suggests ContraFect To Stop Antimicrobial-Resistant Infection Study, CytomX Restructures
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
  
Via Benzinga
Amryt Shares Shoot Higher As FDA Grants Orphan Drug Status To Carcinoid Tumor Candidate
The US Food and Drug Administration (FDA) has granted Orphan Drug Designation to Amryt’s (NASDAQ: AMYT) lead drug Mycapssa for the treatment of carcinoid syndrome. Carcinoid syndrome (CS) is the most... 
Via Benzinga
The Daily Biotech Pulse: F-Star Therapeutics Buyout, Orphan Drug Tag For VBI's Brain Cancer Vaccine, Xenon's Epilepsy Candidate Shows Promise
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
55 Biggest Movers From Friday
Gainers Vallon Pharmaceuticals, Inc. (NASDAQ: VLON) shares jumped 100.9% to close at $2.27 on Friday. Vallon Pharmaceuticals engaged Ladenburg Thalmann & Co Inc to evaluate... 
Via Benzinga
Amryt Pharma's Q4 FY21 Sales, FY22 Guidance Shy Of Street Consensus
Amryt Pharma Plc's (NASDAQ: AMYT) Q4 FY21 sales increased 29% Y/Y to $54.8 million, missing the consensus of $56.81 million. The growth was driven by metreleptin... 
Via Benzinga
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback